This provides a very large base for Lexicon to work off of. Approximately 34 million people are currently living with diabetes in the U.S. Lexicon has illustrated its focus on treating diabetes and diabetic-related conditions. But in the meantime, the company is still developing other drugs. Investors should consider that it will still take some time before the different trials are completed. Additionally, this drug has received a fast track designation from the FDA which is a major hurdle that the company has overcome. Over the course of six weeks, patients at 30 clinical sites will receive either LX9211 or placebo. The goal of this study is to see its efficacy in treating post-herpetic neuralgia. On January 4th, the company announced that it had dosed its first patient in the study of LX9211. This includes agreements with Genentech, Ipsen Pharma SAS, and others. Lexicon has several licensing agreements that are currently underway. In addition, the company is in Phase 3 trials for its drug LX9211, which is utilized in the treatment of Type 2 Diabetes. Top Penny Stocks To Watch If You Like Tech Stocks In January 2021 The company is currently in the development of drugs such as Xermelo, which can treat the side-effects of carcinoid syndrome. This is another clinical-stage biopharmaceutical company working on treating a wide variety of illnesses. was highlighted along with 2 other companies, both of which have followed suit with the LXRX stock trend. In our article, “ Are These Biotech Penny Stocks To Buy Before 2021?” Lexicon Pharmaceuticals Inc. The beginning of December saw traders putting together lists of penny stocks to watch before 2021. Top Robinhood Penny Stocks To Buy Under $1 & 2 Up Big In January 2021īest Penny Stocks to Buy : Lexicon Pharmaceuticals Inc.3 Hot Penny Stocks You Might’ve Missed This Week.With aftermarket momentum pushing shares higher on Friday, will this be another parabolic move for the stock or is another pullback in store? Right now the firm has a Buy rating on BNGO. Furthermore, analysts at Ladenburg Thalmann have followed suit. BNGO, by far, has demonstrated the nature of this excitement. One of the things we’ve seen experience an uptick in attention is genetic research, testing, and therapeutic stocks. This is based on its Saphyr system for scientists and clinicians conducting genetic research and patient testing. The company is currently utilizing genetic testing to help patients suffering from a wide variety of ailments. There is definitely a tradeoff here, but it seems as though BioNano is working to show strength in its financials. Of course, the idea of share dilution is on the table but this deal should add roughly $88 million to its balance sheet. While raises aren’t usually the highpoint with penny stocks, after the announcement, shares of BNGO stock ended up putting in a 14% gain by the end of the day on Friday. The company stated that it would be selling around 29 million shares of common stock for a price of $3.05 per share. While there was some serious consolidation after that move, Friday, the company announced the pricing of its new public stock offering. In fact, since December 28th, we’ve watched BNGO stock skyrocket from around 90 cents to highs of over $7. is one of the companies we’ve discussed in great detail over the last few weeks. ( TRXC Stock Report) “ Hold“īest Penny Stocks To Buy : BioNano Genomics Inc.īioNano Genomics Inc. All things considered, here are four biotech stocks that jumped on January 8th and that analysts appear more bullish on right now. With biotech in focus, however, there are plenty of options that could provide value for investors. These include things like technology and transportation.Īs you can see, it’s important to think outside of the box when looking for penny stocks that may have potential. Outside of biotech and biopharmaceutical companies, there are several other industries benefiting from the pandemic. This is of course due to the effects of the pandemic on world markets and the demand for treatments. Over the past year, we have watched many small-cap biotech companies shoot up in value by substantial amounts. With that in mind, investors seem to be focused on biotech stocks in January. These seem to be two of the most prominent factors that are affecting penny stocks & blue-chip stocks alike right now. Second, day traders & investors should determine how Joe Biden’s presidency will play into the stock market. First, vaccine distribution and how it will affect certain stocks. Now that the year is off to a decent start, there are a few catalysts that remain and to take note of. After a week of volatility in the stock market, Friday represented a relatively calm day for investors. Friday, January 8th was a relatively good day for many penny stocks.
0 kommentar(er)
